Equities researchers at Stephens started coverage on shares of CIGNA (NYSE:CI) in a research report issued to clients and investors on Monday, The Fly reports. The brokerage set an “overweight” rating on the health services provider’s stock.
Several other equities research analysts also recently weighed in on CI. ValuEngine upgraded shares of CIGNA from a “sell” rating to a “hold” rating in a research note on Thursday, January 3rd. Credit Suisse Group reiterated a “buy” rating and set a $250.00 target price on shares of CIGNA in a research note on Monday, January 7th. Zacks Investment Research upgraded shares of CIGNA from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a research note on Friday, January 4th. Barclays reiterated a “buy” rating and set a $220.00 target price on shares of CIGNA in a research note on Sunday, January 6th. Finally, Wells Fargo & Co decreased their target price on shares of CIGNA from $221.00 to $200.00 and set a “market perform” rating for the company in a research note on Thursday, January 3rd. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $228.56.
NYSE CI opened at $194.66 on Monday. The company has a debt-to-equity ratio of 1.61, a current ratio of 0.98 and a quick ratio of 0.98. CIGNA has a 1 year low of $163.02 and a 1 year high of $227.13. The firm has a market capitalization of $46.36 billion, a price-to-earnings ratio of 18.61, a P/E/G ratio of 0.80 and a beta of 0.73.
In other CIGNA news, insider Jason D. Sadler sold 21,189 shares of the stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $212.99, for a total value of $4,513,045.11. Following the completion of the transaction, the insider now directly owns 41,966 shares of the company’s stock, valued at $8,938,338.34. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director William D. Zollars sold 201 shares of the stock in a transaction dated Friday, December 14th. The shares were sold at an average price of $210.84, for a total transaction of $42,378.84. The disclosure for this sale can be found here. Insiders have sold 24,215 shares of company stock valued at $5,160,680 over the last three months. 1.10% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of the business. Edge Wealth Management LLC purchased a new position in shares of CIGNA during the 4th quarter worth approximately $46,000. West Oak Capital LLC acquired a new stake in CIGNA during the fourth quarter worth approximately $84,000. Ancora Advisors LLC acquired a new stake in CIGNA during the third quarter worth approximately $106,000. Acropolis Investment Management LLC acquired a new stake in CIGNA during the fourth quarter worth approximately $100,000. Finally, LFA Lugano Financial Advisors SA acquired a new stake in CIGNA during the third quarter worth approximately $116,000. 93.36% of the stock is owned by institutional investors.
CIGNA Company Profile
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.
Read More: What are Institutional Investors?
Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.